Covid-19 vaccinesrare adverse eventsSARS-CoV-2vaccine efficacyvariants of concernSince the outbreak of coronavirus disease 2019 (Covid-19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of confirmed infections has risen to more than 242...
Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients. JAMA Oncol. 2022 May;8(5):E220446. doi:10.1001/jamaoncol.2022.0446 11. Benning L et al. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) ...
byPublic Library of Science Credit: Unsplash/CC0 Public Domain A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines from Pfizer-BioNTech and Moderna perform better against the World Health Organization's variants of concern (VOCs) than viral vector vaccines from Astra...
It is obvious that a successful COVID-19 vaccination program is needed to end the pandemic and allow a return to normal life5,6. By the end of February 2021, two COVID-19 vaccines had been approved in the U.S.: BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna)7. In two large ...
Very virulent variants may still respond Vaccines were initially developed for protection against COVID-19 strains identified in Wuhan, China, but SARS-CoV-2’s fast mutation rate means efficacy against more transmissible variants of concern (VOCs) and perhaps additional variations of interest is requ...
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given...
It was urgent and necessary to synthesize the evidence for vaccine effectiveness (VE) against SARS-CoV-2 variants of concern (VOC). We conducted a systematic review and meta-analysis to provide a comprehensive overview of the effectiveness profile of COV
AstraZeneca says the drug could benefit some 2% of the population who cannot mount an effective immune response from COVID-19 vaccines. "We hope to make AZD3152 available as a new prophylactic treatment in the second half of this year," said Pangalos. ...
[04:17.52]After another year of face coverings, restrictions, [04:22.48]vaccines and variants, people are beginning [04:26.48]to wonder whether this pandemic will ever go away. [04:30.80]The answer is yes and no. ...
Get vaccinated.Vaccines are still the best public health step to protect people from serious illness from COVID-19. Wear a mask.Your mask will protect you and those around you from all variants. The CDC suggests that you wear a mask in pub...